CONMED Corp (CNMD) Financial Ratio Screen

NYSE Healthcare United States USD 1332M
RATIOS FAIL*
Automated financial screen · activity assessed separately
CONMED Corp (CNMD) is potentially non-compliant in the automated ratio model. The company's debt ratio of 35.9% exceeds the 30% MSCI new-inclusion threshold relative to total assets. CONMED Corp operates in the Healthcare sector.

Follow screening changes

Email alerts are not currently available. Bookmark this page and check the financial period and retrieval date when reviewing a result.

MSCI new-inclusion financial-ratio snapshot

CNMD financial screening at a glance

RATIOS FAIL*Financial ratios shown separately from business review — not a fatwa
Debt ratio
35.9%
Fail vs 30%
Cash ratio
1.8%
Pass vs 30%
Receivables + cash
12.4%
Pass vs 30%
Impermissible income
N/A
Not available vs 5%

Calculation date: 2026-10-15. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria not metAt least one available ratio exceeds its threshold
FTSE/Yasaar-styleFinancial criteria not metAt least one available ratio exceeds its threshold
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-10-15S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style debt and cash reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 35.9%
/ 30%
1.8%
/ 30%
12.4%
/ 30%
N/A RATIOS FAIL*
FTSE 35.9%
/ 33%
1.8%
/ 33%
12.4%
/ 50%
N/A RATIOS FAIL*

Financial Highlights

P/E Ratio
24.0
Forward: 9.3
EPS
currency unverified 1.85
Dividend Yield
0.0%
Payout: 10.8%
P/B Ratio
1.3
EV/EBITDA
9.4
EV: USD 2.1B
Revenue
USD 1.4B
Growth: 0.3%
Beta
0.9
Average volatility
Current Ratio
1.5

Profitability

Gross Margin 55.6%
Operating Margin 14.6%
Net Margin 4.1%
Return on Equity (ROE) 5.5%
Return on Assets (ROA) 4.1%

Cash Flow & Balance Sheet

Operating Cash FlowUSD 171M
Free Cash FlowUSD 151M
Total DebtUSD 835M
Debt-to-Equity80.1
Current Ratio1.5
Total AssetsUSD 2.3B

Price & Trading

Last Close$47.33
50-Day MA$48.03
200-Day MA$40.97
Avg Volume493K
Beta0.9
52-Week Range
$31.44
$53.66

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-10-07 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About CONMED Corp (CNMD)

CEO
Mr. Patrick J. Beyer
Employees
3,900
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NYSE
Market Cap (listing currency)
USD 1332M
Currency
USD

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is CONMED Corp (CNMD) halal to invest in?

The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is CONMED Corp's debt ratio?

CONMED Corp's debt ratio is 35.9% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are CONMED Corp's key financial metrics?

CONMED Corp has a market capitalization of USD 1332M in its listing currency, trailing P/E ratio of 24.0, and revenue of USD 1.4B. The company maintains a gross margin of 55.6% and a net margin of 4.1%. Return on equity stands at 5.5%.

How often is the screening data updated?

Calculation date: 2026-10-15. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.